Sutro Biopharma Reports First Quarter 2024 Financial Results, Business Highlights and Select Anticipated Milestones [Yahoo! Finance]
Vaxcyte, Inc. (NASDAQ: PCVX) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Vaxcyte, Inc. (NASDAQ: PCVX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $95.00 price target on the stock.
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update [Yahoo! Finance]
Vaxcyte Reports First Quarter 2024 Financial Results and Provides Business Update